Tauben Averbuch MD
@TaubenA
Followers
254
Following
489
Media
18
Statuses
158
PGY7 Cardiac Critical Care Fellow at the University of Toronto
Joined May 2019
So grateful to have passed the #Cardiology boards and won the Peter Russell Award. Many thanks to everyone who has trained and supported me along the way - the patients, nurses, allied health, attendings, co-fellows, and family. Special thanks to @hvanspall - the best mentor ever
7
4
54
Last call shift of #Cardiology fellowship done! Many thanks to the wonderful CCU nurses who have supported and taught me along the way. Special thanks to #Sonosite, the real MVP ❤️
1
2
35
In our validation study, we demonstrate that the simple LE index can predict 30d mortality using only length of stay and # of prior ED visits, with better performance than traditional risk scores. Many thanks to @hvanspall and the team!
You can predict 30d ☠️ following #HF #hospitalization w just 2 variables - Length of 🏥stay - n of ED visits in prior 6 mo In an external validation study (n 1206) our simple #LE index performed better than complex #risk scores Each point: ~2x odds of☠️ https://t.co/6WKgFO2aie
0
3
7
In our 5 year sex disaggregated analysis of the #PACTHF trial: 🔴 no sex differences in clinical outcomes, total costs 🔴 high event rates - 65% ☠️, 85% 🏥 🔴⬆️ costs from specialist visits in ♂️, ⬆️ costs from supportive care in ♀️ Many thanks to @hvanspall and the whole team!!
In pragmatic #RCT of 4441 ppl post #HF #hospitalization 5y #prognosis‼️ 65%☠️ 85% 🏥 (avg 3 rehosps pp) #EventRates highest in yr 1 Annual #cost $80.5 K pp, largely from 🏥s No sex differences in event rates & total $, but less specialist care in 👩🏼🦳 https://t.co/OMZo11ytyH
1
4
7
#GlobalRounds @CircAHA visits #Canada 🇨🇦 41 million people Universal healthcare (11% GDP) High life expectancy : healthcare $ Centrally negotiated drug prices And opportunities for improvement👇🏽 How does your #healthcare system compare? @taubenA #KStelkia
https://t.co/X8RnbKCSyD
An overview of the #Canadian healthcare system, #CVD epidemiology, #research & care, and opportunities for growth. Drs. @TaubenA, Stelkia, @hvanspall. @CircAHA
https://t.co/1yJwYCK5Wy
@PHRIresearch @LibinInstitute @FirstNationsBC
6
15
29
Much thanks to @hvanspall and @KStelkia for making this possible!
0
0
4
Our #globalrounds on #CVD care in 🇨🇦 was published in #Circulation 🔑 takeaways: 🔴 universal Healthcare 🔴 high-quality care 🔴 outcomes, wait times comparable to high-income countries 🔴 geography limits delivery of care 🔴 national reporting needed https://t.co/1adg4ss60E
ahajournals.org
1
2
7
🎙️NEW #HeartFailure2024 #LBCT Discussion 💫Dr @hvanspall & Dr @TaubenA discuss the findings from the PACT-HF trial. 📽️Watch here👉 https://t.co/OZiw8ISm4W 📊Clinical outcomes and overall costs following hospitalisation for #HF were similar between male and female patients at
0
4
12
@TaubenA’s first oral presentation & first #LBCT presentation at a meeting, and I dont know who’s more excited!!! #HeartFailure2024
2
3
21
Well noted discussion by Dr Ileana Piña on #PACTHF registries, #LBCT 📍differences in the management between 🧔♂️and👩🦳❓ 📍why more disability❓ 📍less specialized care for 👩🦳, ➡️ we need to do better❤️ #HeartFailure2024
@TaubenA @hvanspall
0
5
13
Incredibly grateful to @hvanspall to present #PACTHF 5yr update at #HeartFailure2024 🔑 findings: 🔴 5 year ☠ = 65% in ♂️ and ♀️ patients 🔴 💲were high, and driven by readmission 🔴 🚫 sex differences in outcomes/costs, but ⬆️ specialist care in ♂️, ⬆️ supportive care in ♀️
How do gender differences impact clinical outcomes and healthcare resource use after #HF hospitalization? #PACTHF registries #LBCT: 📍 64% mortality, 🧔♂️=👩🦳 📍 Higher costs for 🧔♂️ in specialist and invasive care; more home & long-term care for 👩🦳 #HeartFailure2024 @hvanspall
4
9
37
A PACT for the future: Improving medication adherence in #HeartFailure
https://t.co/o1Pde84nWz
@hvanspall @ESC_Journals
4
8
28
Transitional care model following hospitalization for HF: PACT-HF •Intervention: nurse-led home & clinic visits, tailored based on estimated risk •No significant⬇️in primary composite outcome (death, readmission, ED visits), likely because GDMT 🚫⬆️ 💪@TaubenA & team
1
4
12
Our 3 year analysis of the PACT-HF trial, led by the incredible @hvanspall has just been published! We found: 🔴 transitional care did not reduce the composite of death, readmission, or ED visits - likely due to 🚫 change in 💊 🔴 3 year event rates higher than many cancers
In this #clusterRCT of 2495 ppl 🏥for #HF 🔺#transitional (including 🏠 visits & long-term #HF clinics), did not ⬇️ composite ☠️, 🏥, 🚑 at 3y 🔺likely because #GDMT uptake didn’t meaningfully⬆️ 🔺risk HIGHER than invasive cancers: >50%☠️ at 3y https://t.co/ppdDupGvX0 👏 @TaubenA
2
7
29
In our invited editorial on the EVOLUTION-HF study, we discuss the challenges in uptake of #GDMT after #HF hospitalization. Many thanks to our co-authors, @hvanspall and Dr. Greene, as well as @BiykemB and all co-authors for EVOLUTION-HF
#GDMT uptake following 🏥 for #HF: understanding & navigating the 🌎 gaps Invited editorial led by @TaubenA @JACCJournals On @BiykemB et al’s #EvolutionHF study of variation in GDMT uptake across countries using EHR/claims data https://t.co/98JUkEMBkV
https://t.co/rJfsFcbAa3
0
4
13
🔺In this analysis of 136 trials, only 1O% conducted #CompetingRisk analysis 🔺No study accounted for competing risk in sample size calcul’ns 🔺When reporting composite outcomes, consider competing risks (eg ☠️ & 🏥) @HEI_mcmaster #ResearchMethods
4
19
48
Phenomenal work by @hvanspall at #ESCHF, highlighting the challenges in addressing the high-risk transitional care period in #HF
0
3
18
🔴 what's next for UNa? Stay tuned for RCTs that dose diuretics based on UNa 🔴 read the excellent original article here:
pubmed.ncbi.nlm.nih.gov
High UNa after diuretic administration is associated with higher urinary output, greater weight loss, shorter length of stay, and lower odds of death. UNa is a promising marker of diuretic efficacy...
0
0
1